Search
Cartesian Therapeutics Inc
RNACAdd to Watchlist
10.590USD
+0.410+4.03%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
302.29MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.03%
5 Days
+12.42%
1 Month
+61.68%
6 Months
+56.66%
Year to Date
+46.88%
1 Year
-5.53%
Key Figures
10.320Open
10.950High
178.03KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.62%Turnover Ratio
10.180Prev. Close
9.750Low
1.29MTurnover
LossP/E Static
-2.04P/B
0.00%Div Yield TTM
-43.52%ROA
15.57052wk High
0.82Volume Ratio
-77.42MNet Profit
28.54MShares
-5.7921EPS TTM
0.64Beta
-924.61%ROE
5.60052wk Low
11.79%Amplitude
100.00%Gross Margin
302.29MMarket Cap
9.94Reward/Risk
5.57%Risk Rate
TradingKey Stock Score of Cartesian Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Cartesian Therapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 122 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.83.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cartesian Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cartesian Therapeutics Inc Highlights
StrengthsRisks
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.80M.
Fairly Valued
The company’s latest PE is -1.83, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.99M shares, increasing 7.37% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.67.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
33.833
Target Price
+232.35%
Upside Space
Cartesian Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cartesian Therapeutics Inc Info
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Ticker SymbolRNAC
CompanyCartesian Therapeutics Inc
CEOBrunn (Carsten)
Websitehttps://www.cartesiantherapeutics.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Cartesian Therapeutics Inc (RNAC)?
The current price of Cartesian Therapeutics Inc (RNAC) is 10.59.
What is the symbol of Cartesian Therapeutics Inc?
The ticker symbol of Cartesian Therapeutics Inc is RNAC.
What is the 52-week high of Cartesian Therapeutics Inc?
The 52-week high of Cartesian Therapeutics Inc is 15.57.
What is the 52-week low of Cartesian Therapeutics Inc?
The 52-week low of Cartesian Therapeutics Inc is 5.60.
What is the market capitalization of Cartesian Therapeutics Inc?
The market capitalization of Cartesian Therapeutics Inc is 302.29M.
Is Cartesian Therapeutics Inc (RNAC) currently rated as Buy, Hold, or Sell?
According to analysts, Cartesian Therapeutics Inc (RNAC) has an overall rating of Buy, with a price target of 33.83.
What is the Earnings Per Share (EPS TTM) of Cartesian Therapeutics Inc (RNAC)?
The Earnings Per Share (EPS TTM) of Cartesian Therapeutics Inc (RNAC) is -5.02.